• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Methylsulfonylmethane (CH3SO2CH3) administered orally is effective in ameliorating the symptoms of gastrointestinal upset, e.g., produced by the ingestion of aspirin and other pharmaceuticals, and of allergic reactions. Oral compositions containing a mixture of such a pharmaceutical and methylsulfonylmethane are useful in avoiding the gastrointestinal upset which otherwise occurs when ingesting the former.
    公开号:SU1443788A3
    申请号:SU843745552
    申请日:1984-05-11
    公开日:1988-12-07
    发明作者:Джей Гершлер Роберт
    申请人:Роберт Джей Гершлер US)；
    IPC主号:
    专利说明:

    WITH
    00
    k1
    00 00

    cm
    . This invention relates to the chemical and pharmaceutical industry and relates to the preparation of a medicament.
    The purpose of the invention is to increase the shelf life.
    Example 5, O g of anhydrous methylmethyl sulfonate (MSM) s is dissolved in a 25 ml flask heated in an oil bath at a constant temperature. 50 mg of one of the biologically active substances is added to the liquid MSM and mixed until the MSM solution is obtained or its homogeneous suspension: p-dodecylguanidine acetate (fungicides;), p-trichloromethylthio-5-Ciclorexin-1,2-dicarboximide (fungicide); erythromycin, nifurpirinol, methionine; cysteine | corn starch, sucrose acetylsalicylic acid, 1- (p-chlorobenzoyl; -5-labels-C-2-methyltstsol-3-acetic acid, acetaminophene diatepam ;, phenylbutaone; resorcinol, ferric chloride; potassium penicillin Gj benzocaine.
    Pour the resulting solution or suspension onto a sterile sheet of glass and cool to room temperature. Pass the resulting solid sheet of MSM and biologically active compound through a sterile stainless steel sieve (20 mesh) or grind it in a sterile mortar and tablet.
    A tablet formed from 200 mg of MSM, 200 mg of vitamin C, 10 mg of glycine, 10 mg of magnesium stearate, 5. Mg watering of ynylaceta, 5 mg of hydroxypropyl methylcellulose, 10 mg of stearic acid and 10 mg of cetyl alcohol, evenly disintegrated in the imitation gastric juice for 5 hours, after which a complete disintegration was observed.
    A tablet containing 100 mg of MSM 25 mg of penicillin potassium G (or another active agent that must be protected from gastric acid), 10 mg of glycine, 10 mg of calcium stearate, 30 mg of starch, 15 mg of cetyl alcohol and 15 mg of hydrogenated gum, 65% of penicillin potassium G was excreted by the sixth hour and 95% by the tenth hour. In this preparation, the melt of MSM and hydrogenated SMOL was cured to form a solid solution and ground before mixing with other ingredients.
    five
    0
    five
    0
    five
    0
    five
    0
    five
    dientami. By controlling the rate of release from a single dosage form, the active agent can safely pass through the stomach and into more favorable environmental conditions for absorption in the small intestine.
    The effect of MSM on the bioavailability of the pharmaceutical compound (aspirin) was determined using aspirin tablets in 5 granules (0.32 g) of Bayer and tablets formed from 5 granules (0.324 g) of calcium acetyl alicylate i 0.314 g of potassium bicarbonate; 0.0026 g of magnesium stearate and 0.0290 g of MSM (powdered powder containing 2% by weight of food and drug colloidal silicon dioxide). Four tablets of either industrial or test aspirin were introduced in milk and fed after a 12-hour fasting to purebred dogs. During the first 0.5 h with 5 min / t t-bolt and then with 15 g intervals, blood was taken for analysis from each dog. The maximum level in blood with aspirin appeared after 20 min, while with pyty tablets after 15 min. Aspirin was not detected in blood samples after 2.5 hours, while the test tablets provided an assay suitable for analysis, the concentration of asp-schine in the blood 3 hours after the injection of w.
    MSM can be used as a dry granulating auxiliary substance by melting it with a pharmaceutically active agent uniformly dispersed or dissolved in it, solidifying the melt and grinding the resulting solid to granules, which can then be sifted or crushed further up to a free-flowing powder, which can be easily compressed into tablets with improved physical characteristics as compared to properties, as standard using standard aids. Yelnia ruyuschih tabletting agents osobengo sochetanin with a 0.25-2% strength KOJ-.loidalig.y dvuokisg: silicon.
    MSM is particularly useful as a granulant. and a table of choking auxiliaries in food with vi: -a for pharmacologically active substances that are unstable in the presence of moisture, i.e. who lose part or all
    storage activity in the presence of 2% or more of moisture required to work with standard granulating and tableting aids. Therefore, the present invention relates to essentially anhydrous, i.e. containing less than 1% by weight of moisture, mixtures of MSM and one or more pharmaceutically acceptable substances that are unstable when stored in the presence of moisture, such as vitamins.
    The positive effect is an increase in shelf life, in the creation of chemically and moisture-active} active compounds in solid form in an anhydrous state. Conventional excipients require moisture for proper function.
    can be used as granulating, tabletting agents, which reduces the expected service life of substances in solid form.
    权利要求:
    Claims (1)
    [1]
    Invention Formula
    The method of obtaining solid drug formaz by mixing the active substance with a solid excipient followed by tabletting, characterized in that, in order to increase the shelf life, methylsulfonylmethane is added as an auxiliary substance in a dry state or it is pre-melted, then cooled to a solidification temperature and subjected to dry granulation.
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1443788A3|1988-12-07|Method of producing solid medicine
    KR890004688B1|1989-11-25|Sustained release pharmaceutical carrier compositions
    CA1338889C|1997-02-04|Morphine containing composition
    US3488418A|1970-01-06|Sustained relief analgesic composition
    EP1027037B1|2003-12-03|Pharmaceutical preparation comprising clodronate as active ingredient and silicified microcrystalline cellulose as excipient
    AU636810B2|1993-05-06|Delivery system for enhanced onset and increased potency
    US4950484A|1990-08-21|Pharmaceutical tablet, pharmaceutical granulate and process for their preparation
    US5211958A|1993-05-18|Pharmaceutical composition and process for its preparation
    KR100891887B1|2009-04-03|Medicinal preparation containing 5-methyl-1-phenyl-2-|-pyridone as active ingredient
    AU2002238848B2|2007-11-15|Use of a spray-dried powder comprising a sugar alcohol
    BG65007B1|2006-12-29|Fast melting oral dosage form
    EA001537B1|2001-04-23|Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a great amount of medicaments
    NL8500724A|1986-10-01|DEVICES FOR REGULAR RELEASE OF ACTIVE SUBSTANCES AND METHOD OF MANUFACTURE THEREOF
    SK116097A3|1998-03-04|A pharmaceutical composition stabilized by alkaline agent
    JP2009524658A|2009-07-02|Levetiracetam preparation and method for producing the same
    EP0749308B1|2003-05-14|Film coated tablet of paracetamol and domperidone
    BG64348B1|2004-11-30|Paracetamol-containing tablet medicamentous form for swallowing
    US3524910A|1970-08-18|Sustained relief analgesic compositions
    EP0500851B1|1995-03-08|Process for the preparation of a tablet or dragee composition containing a heat-, light- and moisture-sensitive active ingredient having monoclinic crystal structure
    US5079007A|1992-01-07|Controlled release of antibiotic salts from an implant
    SU1009467A1|1983-04-07|Agent for dissoluting urine concretions
    RU2197244C2|2003-01-27|Pharmaceutical composition and pharmaceutical preparation comprising oxaprozine potassium, sodium and tris salts, their application for pain relief or weakening in mammal and for treatment of inflammation and disorders associated with inflammation in mammal, method of pharmaceutical preparation preparing
    CN1352558B|2012-06-13|Immediate release medicinal compositions for oral use
    JP4864369B2|2012-02-01|Method for stabilizing thiamines
    EP0319074B1|1992-01-29|Pharmaceutical composition and process for its preparation
    同族专利:
    公开号 | 公开日
    DK238384D0|1984-05-14|
    DE3382136D1|1991-02-28|
    JPS59501748A|1984-10-18|
    EP0103836A3|1986-07-30|
    NZ205571A|1986-09-10|
    AT60234T|1991-02-15|
    PH20568A|1987-02-18|
    AU564536B2|1987-08-13|
    DK238384A|1984-05-14|
    CA1219218A|1987-03-17|
    NO841909L|1984-05-11|
    US4514421A|1985-04-30|
    EP0103836B1|1991-01-23|
    AU7473287A|1987-10-08|
    WO1984001105A1|1984-03-29|
    AU599670B2|1990-07-26|
    AU2039683A|1984-04-04|
    EP0103836A2|1984-03-28|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    IL26209A|1965-08-02|1970-10-30|Merck & Co Inc|Pharmaceutical compositions containing substituted sulphones|
    US4333922A|1974-09-12|1982-06-08|Herschler R J|Method for the treatment of water-living animals with health modifying agents|
    US4514421A|1979-08-30|1985-04-30|Herschler R J|Dietary and pharmaceutical uses of methylsulfonylmethane and compositions comprising it|
    US4296130A|1979-08-30|1981-10-20|Herschler R J|Methylsulfonylmethane and methods of use|US4863748A|1979-08-30|1989-09-05|Herschler R J|Dietary products and uses comprising methylsulfonylmethane|
    US4514421A|1979-08-30|1985-04-30|Herschler R J|Dietary and pharmaceutical uses of methylsulfonylmethane and compositions comprising it|
    US4914135A|1979-08-30|1990-04-03|Herschler R J|Use of Methylsulfonylmethane to treat parasitic infections|
    US4616039A|1979-08-30|1986-10-07|Herschler R J|Methylsulfonylmethane in dietary products|
    GB9218711D0|1992-09-04|1992-10-21|Salim Aws S M|Skin cancer treatment|
    AU4974893A|1992-09-04|1994-03-29|Aws Shakir Mustafa Salim|Skin treatment compositions containing dimethylsulphone and allopurinol or oxypurinol|
    US6426085B1|1994-05-02|2002-07-30|Josman Laboratories Inc.|Use of bismuth-containing compounds in topical oral dosage forms for the treatment of halitosis|
    US5834002A|1994-05-02|1998-11-10|Josman Laboratories, Inc.|Chewing gum containing colloidal bismuth subcitrate|
    US6902738B2|1994-05-02|2005-06-07|Josman Laboratories, Inc.|Topical oral dosage forms containing bismuth compounds|
    US5569679A|1994-12-30|1996-10-29|Russell A. Krueger Pharmaceuticals, Inc.|Pharmacologic management of snoring|
    US6372784B1|1995-02-07|2002-04-16|Josman Laboratories, Inc.|Bismuth-containing compounds in topical dosage forms for treatment of corneal and dermal wounds|
    WO1997007757A1|1995-08-24|1997-03-06|Josman Laboratories, Inc.|Bismuth-containing compounds in topical dosage forms|
    US6379651B1|1995-02-07|2002-04-30|Josman Laboratories|Oral-topical dosage forms for delivering antibacterials/antibiotics to oral cavity to eradicate H. pylori as a concomitant treatment for peptic ulcers and other gastro-intestinal diseases|
    WO1996035435A1|1995-05-09|1996-11-14|The Procter & Gamble Company|Compositions containing bismuth, for the treatment and prevention of gastrointestinal disorders|
    US5702729A|1995-12-07|1997-12-30|The Procter & Gamble Company|Methods for the prevention and treatment of gastrointestinal disorders caused or mediated by algae or cyanobacteria|
    US6051604A|1995-12-07|2000-04-18|The Proctor & Gamble Company|Methods and compositions for the prevention and treatment of gastrointestinal disorders|
    NO314979B1|1995-12-07|2003-06-23|Procter & Gamble|Use of bismuth for the preparation of a preparation for the treatment or prevention of a urogenital disorder|
    WO1997020566A1|1995-12-07|1997-06-12|The Procter & Gamble Company|Compositions, containing bismuth, for the prevention and treatment of gastrointestinal disorders|
    US5827543A|1995-12-07|1998-10-27|The Procter & Gamble Company|Methods and compositions for the prevention and treatment of urogenital disorders|
    US5744168A|1995-12-07|1998-04-28|The Procter & Gamble Company|Methods and compositions for the prevention and treatment of gastrointestinal disorders|
    US7718694B2|1997-10-16|2010-05-18|Children's Hospital & Research Center At Oakland|Compositions and methods for therapy for diseases characterized by defective chloride transport|
    US6203820B1|1998-05-28|2001-03-20|Brice E. Vickery|Compositions and methods for enhancing protein anabolism and detoxification|
    AT355846T|1999-10-04|2007-03-15|John Carter|PHARMACEUTICAL COMPOSITION CONTAINING COPPER, SALICYLIC ACID AND VITAMIN C|
    US6787164B2|2000-02-23|2004-09-07|Bioselect Innovations, Inc.|Composition and method for treating the effects of diseases and maladies|
    US6793942B2|2000-02-23|2004-09-21|Bioselect Innovations, Inc.|Composition and method for treating the effects of diseases and maladies|
    US6841544B2|2000-02-23|2005-01-11|Bioselect Innovations, Inc.|Composition and method for treating the effects of diseases and maladies|
    US6759062B2|2000-02-23|2004-07-06|Bioselect Innovations, Inc.|Composition and method for treating the effects of diseases and maladies|
    US6403116B1|2000-11-03|2002-06-11|Triarco Inductries, Inc.|Coenzyme Q10 formulation|
    US20040038864A1|2002-06-27|2004-02-26|Per Balschmidt|Use of dimethyl sulfone as isotonicity agent|
    US20040029774A1|2002-08-06|2004-02-12|Aly Gamay|Composition and methods for the treatment of musculoskeletal disorders and collagen and elastin deficiencies|
    US20040082667A1|2002-10-16|2004-04-29|Mccadden Kenneth|Hangover treatment|
    JP2005298412A|2004-04-13|2005-10-27|Minato Pharmaceutical Co Ltd|Coated particle|
    WO2005112667A1|2004-05-20|2005-12-01|Takashi Omori|Health food|
    ITBS20040068A1|2004-05-24|2004-08-24|Gen Topics Srl|COSMETIC AND / OR PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ROSACEA|
    US20060147423A1|2004-12-07|2006-07-06|Jean-Yves Legendre|Transungual device|
    US8480797B2|2005-09-12|2013-07-09|Abela Pharmaceuticals, Inc.|Activated carbon systems for facilitating use of dimethyl sulfoxideby removal of same, related compounds, or associated odors|
    EP2324838A1|2005-09-12|2011-05-25|Abela Pharmaceuticals, Inc.|Compositions Comprising Dimethyl Sulfoxide |
    US8435224B2|2005-09-12|2013-05-07|Abela Pharmaceuticals, Inc.|Materials for facilitating administration of dimethyl sulfoxideand related compounds|
    CA2622204C|2005-09-12|2016-10-11|Abela Pharmaceuticals, Inc.|Systems for removing dimethyl sulfoxideor related compounds, or odors associated with same|
    US7754256B2|2007-03-07|2010-07-13|Stan Dennison|Nutritional composition|
    BRPI0921494A2|2008-11-03|2018-10-30|Prad Reasearch And Development Ltd|method of planning a underground forming sampling operation, method of controlling a underground forming sampling operation, method of controlling a drilling operation for an underground formation, and method of sampling during the drilling operation.|
    CN102548396A|2009-04-30|2012-07-04|贝克特里弗里特公司|Composition for sterilizing surfaces|
    US9855212B2|2009-10-30|2018-01-02|Abela Pharmaceuticals, Inc.|Dimethyl sulfoxideor DMSO and methylsulfonylmethaneformulations to treat infectious diseases|
    JP5651186B2|2009-10-30|2015-01-07|バイオジェニック イノベーションズ， リミテッド ライアビリティ カンパニー|Methylsulfonylmethanefor treating drug-resistant microorganisms|
    WO2011123695A1|2010-03-31|2011-10-06|Abela Pharmaceuticals, Inc.|Dimethy sulfoxxideformulations for treating autism|
    MX355103B|2012-04-02|2018-04-05|Eaglepharma Pty Ltd|COMPOSITION FOR THE TREATMENT OF INFLAMMATORY and IMMUNE DISORDERS.|
    WO2016010284A1|2014-07-16|2016-01-21|유한회사 비엔트리니티|Toothpaste composition containing curcuma longa l., and preparation method therefor|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    US06/418,110|US4514421A|1979-08-30|1982-09-14|Dietary and pharmaceutical uses of methylsulfonylmethane and compositions comprising it|
    [返回顶部]